News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene Corporation (CELG) Announces Pomalidomide Will be Reviewed at FDA Advisory Committee


9/19/2012 10:02:07 AM

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of the Company’s new drug application (NDA) for pomalidomide at its meeting on November 8, 2012. The Company is seeking approval to market pomalidomide in combination with dexamethasone as a potential treatment for patients with relapsed and refractory multiple myeloma that has progressed following at least two prior therapies. The agency has set a Prescription Drug User Fee Act (PDUFA) date of Feb. 10, 2013 for completion of the review.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES